Apimeds Pharmaceuticals US (APUS) Enterprise Value (2023 - 2025)

Apimeds Pharmaceuticals US has reported Enterprise Value for 3 years, with the latest figure at -$3.6 million in Q4 2025.

• For the quarter ending Q4 2025, Enterprise Value fell 105157.74% year-over-year to -$3.6 million; the trailing twelve-month figure through Dec 2025 stood at -$3.6 million (down 105157.74% YoY), and the FY2025 full-year result was -$3.6 million, down 105157.74% from the prior year.
• Enterprise Value for Q4 2025 stood at -$3.6 million, up from -$7.0 million in the prior quarter.
• The five-year high for Enterprise Value was -$3455.0 in Q4 2024, with the low at -$8.7 million in Q2 2025.
• Historically, Enterprise Value has averaged -$3.3 million across 3 years, with a median of -$2.0 million in 2023.
• Annual changes were most pronounced in 2024 — Enterprise Value soared 99.16% — and 2025, when it sank 105157.74%.
• Apimeds Pharmaceuticals US's Enterprise Value stood at -$410481.0 in 2023, then soared by 99.16% to -$3455.0 in 2024, then slumped by 105157.74% to -$3.6 million in 2025.
• The last three Enterprise Value figures came in at -$3.6 million (Q4 2025), -$7.0 million (Q3 2025), and -$8.7 million (Q2 2025), per Business Quant data.